

reactivation caused disseminated infection thereafter, as reported in AIDS patients. Recently, the prognosis of CGD patients has improved substantially because of prophylaxis with antibiotics and the prophylactic use of IFN- $\gamma$  [5]. Furthermore, unusually late diagnosis (13–43 years of age) of CGD has been reported [5]. The presented case suggests that CGD could be one of the underlying conditions for BCG-osis or BCG-itis in adolescents or adults long after vaccination.

BCG and *M. tuberculosis* are among the important pathogens in primary immunodeficiency diseases (PID) including CGD. BCG lymphadenitis and tuberculous lymphadenitis are indistinguishable in clinical manifestations, histological findings, and PCR amplification. PCR using Cobas Amplicor® test detects *M. bovis* BCG as well as *M. tuberculosis*, since both of them belong to the *M. tuberculosis* complex. However, the treatment and prognosis of the two conditions are different. The whole-blood IFN- $\gamma$  assay has been considered to be superior to tuberculin skin test in its high specificity. In contrast to *M. tuberculosis* and *M. bovis*, *M. bovis* BCG has a lost region of difference 1 (RD1) gene, in which early secreted antigenic target 6-kDa protein (ESAT-6) and 10-kDa culture filtrate protein (CFP-10) are encoded, and its infection does not lead to IFN- $\gamma$  production by blood cells in response to ESAT-6 or CFP-10 in the assay. The presented case also suggests that the whole-blood IFN- $\gamma$  assay might be useful in differentiating BCG infection and tuberculosis in patients with PID, as long as the patient's ability to produce IFN- $\gamma$  is preserved.


**Acknowledgments** The authors thank Prof. Hiroyuki Nunoi (Department of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan) for the genotyping of the patient with X-linked CGD

and Dr. Masaaki Seki (Japan BCG Laboratory, Tokyo, Japan) for the identification of isolated mycobacterium. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 19591254) and Health and Labour Sciences Research Grants for Primary Immunodeficiency Diseases, for Tuberculosis, and for Vaccination from the Ministry of Health, Labour and Welfare of Japan.

## References

- Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chappier A, Filipe-Santos O, Feinberg J, Emile JF, Kutukculer N, Casanova JL (2007) BCG-osis and tuberculosis in a child with chronic granulomatous disease. *J Allergy Clin Immunol* 120:32–38
- Filipe-Santos O, Bustamante J, Chappier A, Vogt G, de Beaucoudrey L, Feinberg J, Jouanguy E, Boisson-Dupuis S, Fieschi C, Picard C, Casanova JL (2006) Inborn errors of IL-12/23- and IFN- $\gamma$ -mediated immunity: molecular, cellular, and clinical features. *Semin Immunol* 18:347–361
- Lamhamedi-Cherradi S, de Chastellier C, Casanova JL (1999) Growth of *Mycobacterium bovis*, Bacille Calmette-Guérin, within human monocytes-macrophages cultured in serum-free medium. *J Immunol Methods* 225:75–86
- Lee PP, Chan KW, Jiang L, Chen T, Li C, Lee TL, Mak PH, Fok SF, Yang X, Lau YL (2008) Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. *Pediatr Infect Dis J* 27:224–230
- Liese JG, Jendrossek V, Jansson A, Petropoulos T, Kloos S, Gahr M, Belohradsky BH (1996) Chronic granulomatous disease in adults. *Lancet* 347:220–223
- Sasaki Y, Nomura A, Kusuhara K, Takada H, Ahmed S, Obinata K, Hamada K, Okimoto Y, Hara T (2002) Genetic basis of patients with bacille Calmette-Guérin osteomyelitis in Japan: identification of dominant partial interferon-gamma receptor 1 deficiency as a predominant type. *J Infect Dis* 185:706–709
- Seki M, Sato A, Honda I, Yamazaki T, Yano I, Koyama A, Toida I (2005) Modified multiplex PCR for identification of Bacillus Calmette-Guérin substrain Tokyo among clinical isolates. *Vaccine* 23:3099–3102

Provided for non-commercial research and education use.  
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



ELSEVIER

Contents lists available at ScienceDirect

Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease

Akitsugu Furumoto<sup>a</sup>, Yasushi Ohkusa<sup>e</sup>, Meng Chen<sup>a</sup>, Kenji Kawakami<sup>b</sup>, Hironori Masaki<sup>c</sup>, Yoshiko Sueyasu<sup>d</sup>, Tomoaki Iwanaga<sup>d</sup>, Hisamichi Aizawa<sup>d</sup>, Tsuyoshi Nagatake<sup>a</sup>, Kazunori Oishi<sup>a,f,\*</sup>

<sup>a</sup> Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

<sup>b</sup> Department of Respiratory Medicine, Nagasaki Medical Center of Neurology, Nagasaki, Japan

<sup>c</sup> Department of Internal Medicine, Tagami Hospital, Nagasaki, Japan

<sup>d</sup> Department of First Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan

<sup>e</sup> Information Center for Infectious Disease, National Institute of Infectious Disease, Tokyo, Japan

<sup>f</sup> Laboratory for Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

### ARTICLE INFO

#### Article history:

Received 25 June 2007

Received in revised form 6 May 2008

Accepted 19 May 2008

Available online 5 June 2008

#### Keywords:

Pneumococcal vaccine

Influenza vaccine

Acute exacerbation

Chronic lung diseases

Chronic obstructive pulmonary diseases

### ABSTRACT

To determine the clinical efficacy of combined vaccination with 23-valent pneumococcal vaccine (PV) and influenza vaccine (IV) against pneumonia and acute exacerbation of chronic lung diseases (CLD), we conducted an open-label, randomized, controlled study among 167 adults with CLD over a 2-year period. Subjects were randomly assigned to a PV+IV group ( $n=87$ ) or an IV group ( $n=80$ ). The number of patients with CLD experiencing infectious acute exacerbation ( $P=0.022$ ), but not pneumonia ( $P=0.284$ ), was significantly lower in the PV+IV group compared with the IV group. When these subjects were divided into subgroups, an additive effect of PV with IV in preventing infectious acute exacerbation was significant only in patients with chronic obstructive pulmonary diseases ( $P=0.037$ ). In patients with CLD, the Kaplan–Meier survival curves demonstrated a significant difference for infectious acute exacerbation ( $P=0.016$ ) between the two groups. An additive effect of PV with IV on infectious acute exacerbation was found during the first year after vaccination ( $P=0.019$ ), but not during the second year ( $P=0.342$ ), and was associated with serotype-specific immune response in sera of these patients who used PV during the same period.

© 2008 Elsevier Ltd. All rights reserved.

### 1. Introduction

Acute exacerbation frequently occurs among patients with chronic lung diseases (CLD), such as chronic obstructive pulmonary disease (COPD) and sequelae of pulmonary tuberculosis (SPTB) [1,2]. Morbidity, mortality and health-care costs of these patients largely result from on acute exacerbations [3]. Acute exacerbations are primarily triggered by bacterial or viral pathogens in COPD and SPTB. While *Streptococcus pneumoniae* (*S. pneumoniae*) is the most commonly identified cause of community-acquired pneumonia (CAP) by accounting for 16.5–38.9% of CAP among adults [4,5],

this pathogen is also responsible for 8–25% of acute exacerbation in patients with CLD or COPD, which makes it a major bacterial pathogen [2,6,7]. Viral pathogens are also capable of inducing acute exacerbation of COPD, and the influenza virus was frequently detected in 5–29% of exacerbation of COPD [8,9].

Since antibodies to pneumococcal capsular polysaccharide (PPS) and complement provide protection against *S. pneumoniae* with homologous or cross-reactive capsular serotypes [10], pneumococcal polysaccharide vaccine (PV) is effective for preventing invasive pneumococcal diseases in patients with chronic illness, such as CLD. PV is, therefore, recommended for these patients [11–13]. Although the previous studies reported that PV is not effective in preventing pneumonia or acute exacerbation in patients with COPD [14–16], a recent, prospective study demonstrated an effect of PV in preventing pneumonia in such patients with less than 65 years of age with severe airflow obstruction [17]. In addition, a retrospective study previously reported the additive effects of PV with influenza vaccine (IV) in the reduction of hospitalization

\* Corresponding author at: Laboratory for Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, 565-0871 Osaka, Japan.  
Tel.: +81 6 6879 4253; fax: +81 6 6879 4255.

E-mail address: [oishik@biken.osaka-u.ac.jp](mailto:oishik@biken.osaka-u.ac.jp) (K. Oishi).

stays and death among elderly persons with CLD [18,19]. Although a large-scale prospective study demonstrated the additive effects of PV and IV in reducing hospital mortality due to pneumonia among elderly persons [20], no prospective study has been conducted to find the additive effects of PV combined IV for preventing pneumonia or acute exacerbation in patients with CLD. This open-label, randomized, controlled study was designed to determine whether PV and IV combined are superior to IV alone in preventing pneumonia or acute exacerbation among patients with CLD.

## 2. Materials and methods

### 2.1. Study design

For this study, 191 patients with CLD in a stable condition were enrolled after providing written informed consent at the respiratory clinic of 13 hospitals in the district of Kyushu and Okinawa, Japan between November 2001 and April 2002. All potentially eligible subjects (at least twice as many as the enrolled cases) were contacted by the members of the Pneumococcal Vaccine Trialist Group, belonging to one of these hospitals. As the study investigators, these doctors had a role in selecting the subjects for the study enrollment. Inclusion criteria were patients with CLD who previously experienced acute exacerbations, were able to comply with a schedule of monthly clinical visits and were between 40 and 80 years of age. Patients who were pregnant or had immunocompromised conditions such as active malignant diseases, renal insufficiency in dialysis or HIV infection, hypogammaglobulinemia or anatomical or functional asplenia and who had previously received 23-valent PV (Pneumovax, Banyu, Japan) were excluded. The enrollees were randomly assigned in equal proportion to either the group receiving PV and IV (The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) or IV alone. By sealed envelope, each study site was randomly allocated either 10 or 20 cases. Equal numbers of sealed envelopes each containing a card indicating either the PV+IV group or the IV group were prepared, and each study participant chose an envelope. This vaccine allocation was done by the study investigators. In addition, the doctors who screened the subjects also conducted the exclusions and enrollments.

While the participants in the PV+IV group were separately immunized with 0.5 ml of PV and 0.5 ml of IV on separate occasions in 1 month intervals, the participants in the IV group were immunized with 0.5 ml of IV alone. All participants received IV once in both the 2001/2002 and 2002/2003 seasons. For this study, our group used a trivalent, split-virion, influenza vaccine, containing A/NewCaledonia/20/99H1N1, A/Panama/2007/99H3N2, and B/Johannesburg/5/99 for the 2001/2002 season; and for the 2002/2003 season, the study was conducted using vaccine containing A/NewCaledonia/20/99H1N1, A/Panama/2007/99H3N2 and B/Guangdong/7/97.

Demographic data were obtained from each participant at the time of enrollment. All participants were examined, typically once a month, at each hospital by physicians who were the members of the Pneumococcal Vaccine Trialist Group at each study hospital in the Kyushu and Okinawa districts. Patients were also asked to visit each study hospital for examination by a study physician, if they developed a fever, cough and sputum, or experienced breathlessness during the 2-year follow-up period.

To monitor the concentrations of anti-PPS IgG, serum samples were collected from the patients of the PV+IV group immediately before and at 1 month, 6 months, 1 year, and 2 years after the initial pneumococcal vaccination. Separated sera were stored frozen at




Fig. 1. Flow diagram of study patients with chronic lung disease.

–80 °C until used. All studies described herein were approved by the institutional review board of each institution.

### 2.2. Study population

One hundred and ninety-one patients with CLD were assigned to either the PV+IV group ( $n=94$ ) or to the IV group ( $n=97$ ) (Fig. 1). During 2-year follow-up period, 2 and 11 subjects were lost from the PV+IV group and IV groups, respectively. In addition, an early termination of follow-up occurred for 5 subjects for the PV+IV group and for 6 subjects in the IV group because they wanted to withdraw from the study. Subsequently, 87 subjects in the PV+IV group and 80 subjects in the IV group completed the analysis.

### 2.3. Outcome measures

The outcome measured was recorded as either the time to the first episode of pneumonia or to acute exacerbation after the enrollment in this study. A pneumonia diagnosis was based on either clinical symptoms (cough, sputum or fever) plus increased white blood cell counts or serum C-reactive protein, and the appearance of a new infiltration on a chest radiograph [21]. Acute exacerbation in CLD was defined by criteria as previously described [22]: (1) increased dyspnea, (2) increased sputum volume and (3) increased sputum purulence, and (4) absence of newly appeared infiltration on a chest radiograph. Acute exacerbation was diagnosed when two of the three respiratory symptoms existed or when one of these and one of additional symptoms, such as a fever without any other causes or increased cough was present [23]. When the laboratory examinations revealed an increase in their white blood cell counts or serum C-reactive protein, in addition to the clinical symptoms of acute exacerbation, patients were diagnosed as infectious acute exacerbation, and were therefore classified into one of two categories: either infectious or non-infectious acute exacerbation. Furthermore, when *S. pneumoniae* was isolated from purulent sputum in cases of acute exacerbation, patients were diagnosed as pneumococcal acute exacerbation as a subcategory of infectious acute exacerbation.

### 2.4. Measurement of anti-PPS IgG

Serum samples for serotype-specific IgG were available from only 35 of 87 patients with CLD in the PV+IV group for all intervals—1 month, 6 months, 1 year, and 2 years. 7 subjects died during the 2-year period, and 45 of the remaining subjects lacked at least one serum sample from the time interval at either 6 months, 1 year or 2 years. The concentrations of serotype-specific IgG were measured as previously described elsewhere [24]. The US reference

pneumococcal antiserum (89-SF), courtesy of Dr. Carl Frasch, was adsorbed to CWPS, but all other samples were adsorbed to CWPS (5 µg/ml) and 22F PPS (10 µg/ml) [25]. Serotype-specific IgG was determined for the four serotypes (6B, 14, 19F and 23F) that are the most prevalent among adult patients with pneumococcal infections in the US and Japan [5,26].

### 2.5. Statistical analysis

The case numbers of patients with COPD, SPTB, and other CLDs, and the case number of patients experiencing pneumonia, infectious acute exacerbation, pneumococcal acute exacerbation, and non-infectious acute exacerbation and the case numbers of death were compared using a  $\chi^2$ -test. A Kaplan–Meier estimator was used to calculate the survival curve for subjects who developed neither pneumonia nor infectious or non-infectious acute exacerbation during the 2-year study period. The Cox's proportional hazard model was used to evaluate the effect of PV on the incidence of pneumonia and infectious or non-infectious exacerbation both in the first and second 1-year. The effects of age (age older than 55 years, 65 years, and older than 75 years) and female sex were considered in multivariate analysis. Differences in geometric mean concentrations (GMCs) of serotype-specific IgG over time were assessed using the Wilcoxon signed-ranks test. An interim target sample size of 82 was chosen to ensure that there would be at least an 80% chance to detect a difference of 0.2 (0.2 vs. 0.4) episodes per person per year, with a one-sided alpha level of 0.05, in the frequency of admission due to pneumonia between groups of PV+IV and IV. Data was considered to be statistically significant, if the *P* values were less than 0.05.

### 3. Results

Ages (mean  $\pm$  S.D. years) and male sex (%) were  $69.0 \pm 9.0$  and 63.5 for total subjects,  $67.8 \pm 9.5$  and 69.0 for the PV+IV group, and  $70.1 \pm 7.4$  and 57.5 for the IV group. The numbers of patients with three subcategories of CLD (COPD, SPTB and other CLDs) in the PV+IV and the IV groups are shown in Table 1. Other CLDs were bronchiectasis ( $n=20$ ; 10 for the PV+IV group and 10 for the IV group), bronchial asthma ( $n=13$ , 6 for the PV+IV group and 7 for the IV group), pneumoconiosis ( $n=14$ , 7 for the PV+IV group and 7 for the IV group), interstitial pneumonia ( $n=9$ , 3 for the PV+IV group and 6 for the IV group), diffuse panbronchiolitis ( $n=5$ , 4 for the PV+IV group and 1 for the IV group), and sarcoidosis ( $n=1$  for the IV group). Fifty-nine subjects received home oxygen therapy




Fig. 2. Kaplan–Meier survival curves for patients with chronic lung diseases (CLD) showing the proportion of subjects free from pneumonia (A) and infectious acute exacerbation (B) between PV+IV group and IV group during the follow-up period.

(HOT) (27 for the PV+IV and 32 for the IV), and 11 subjects (6 for the PV+IV and 5 for the IV) were treated with noninvasive positive pressure ventilation (NPPV). While a significant difference was found in the number of patients with SPTB between the two groups, no significant difference was found in the number of patients with COPD or other CLDs, nor in the number of patients receiving either HOT or NPPV.

The incidence of pneumonia (0.096 episodes/(patient year)) with CLD in this study was twice as higher as those of previous cohort studies of COPD patients (0.047–0.055 episodes/(patient year)) [14,17]. No significant difference was found in the number of patients developing pneumonia between the PV+IV group and the IV group (Table 1). Similarly, no significant difference was found in the Kaplan–Meier survival curves for pneumonia between the two groups ( $P=0.399$ , Fig. 2A).

Table 1  
Demographic features and outcome of patients with chronic lung diseases (CLD)

Characteristics	No. of patients (%)		P-value	
	All subjects (n=167)	PV+IV group (n=87)		IV group (n=80)
<b>Subcategories of CLD</b>				
COPD	55 (32.9)	24 (27.6)	31 (38.8)	0.125
Sequelae of pulmonary tuberculosis	50 (30.0)	33 (37.9)	17 (21.3)	0.018
Other CLDs	62 (37.1)	30 (34.5)	32 (40.0)	0.461
<b>Outcome</b>				
Pneumonia	25 (32.9)	13 (27.6)	12 (38.8)	0.284
<b>Acute exacerbation</b>				
Infectious	76 (45.5)	32 (36.8)	44 (55.0)	0.022
Pneumococcal	6 (3.6)	1 (1.1)	5 (6.3)	0.106
Non-infectious	15 (9.0)	9 (10.3)	6 (7.5)	0.557
Death	14 (8.4)	7 (8.0)	7 (8.8)	0.870

PV: pneumococcal polysaccharide vaccine, IV: influenza vaccine, COPD: chronic obstructive pulmonary disease. Acute exacerbations are classified into two categories: infectious and non-infectious acute exacerbation. Infectious acute exacerbation involves pneumococcal acute exacerbation.

**Table 2**

Outcome of patients with COPD, sequelae of pulmonary tuberculosis (SPTB) and other chronic lung diseases (CLDs) by vaccine group during 2 years after vaccination

Subcategories of CLD/outcome	No. of patients (%)		P-value
	PV+IV group (n=87)	IV group (n=80)	
<b>COPD</b>			
Pneumonia	6 (6.9)	5 (6.3)	0.615
Acute exacerbation			
Infectious	9 (10.3)	21 (26.3)	0.037
Non-infectious	5 (5.7)	2 (2.5)	0.315
<b>SPTB</b>			
Pneumonia	3 (3.4)	2 (2.5)	0.218
Acute exacerbation			
Infectious	10 (11.5)	7 (8.7)	0.442
Non-infectious	2 (2.3)	3 (3.8)	0.594
<b>Other CLDs</b>			
Pneumonia	4 (4.6)	5 (6.3)	0.379
Acute exacerbation			
Infectious	13 (14.9)	16 (20.0)	0.599
Non-infectious	2 (2.3)	1 (1.3)	0.616

PV: pneumococcal polysaccharide vaccine, IV: influenza vaccine, COPD: chronic obstructive pulmonary diseases. Acute exacerbations are classified into two categories: infectious and non-infectious acute exacerbation.

The incidence of acute exacerbation (0.53 episodes/(patient year)) in this study was slightly lower than those of previous studies of COPD patients (0.85–1.08 episodes/(patient year)) [27,28]. No significant difference was found in the number of CLD patients with pneumococcal acute exacerbation ( $P=0.106$ ) or non-infectious acute exacerbation ( $P=0.557$ ) between the two groups (Table 1). In contrast, a significant difference was found in the number of CLD patients with infectious acute exacerbation ( $P=0.022$ ) between the two groups (Table 1). The Kaplan–Meier survival curves for CLD patients with infectious acute exacerbation ( $P=0.016$ , Fig. 2B) also demonstrated a significant difference between the two groups. However, no significant difference was found in the mortality during the 2-year period after vaccination in both groups (Table 1).


Furthermore, we examined the number of patients experiencing pneumonia and infectious or non-infectious acute exacerbation in each subcategory (Table 2). No significant difference was found in the number of patients with COPD, SPTB and other CLDs experiencing either pneumonia or non-infectious acute exacerbation. In contrast, a significant difference was found in the number of patients with COPD experiencing infectious acute exacerbation ( $P=0.037$ ), but not in the number of patients with SPTB ( $P=0.442$ ) or other CLDs ( $P=0.599$ ). In COPD patients, the

**Table 3**

Estimated result of Cox's proportional hazard model for pneumonia, infectious acute exacerbation, and non-infectious acute exacerbation in patients with chronic lung diseases during the first and the second year

Period	Variables	Pneumonia		Acute exacerbation, infectious		Acute exacerbation, non-infectious	
		Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
First year	PV	0.70 (0.31–1.60)	0.402	0.58 (0.37–0.91)	0.019	1.40 (0.50–3.94)	0.522
	PV	0.72 (0.32–1.68)	0.452	0.56 (0.35–0.90)	0.016	1.56 (0.54–4.52)	0.411
	Age older than 55 years old	N.A.	N.A.	1.02 (0.33–3.12)	0.973	1.97 (0.22–17.4)	0.543
	Age older than 65 years old	1.05 (0.13–8.52)	0.963	1.15 (0.40–3.27)	0.798	0.33 (0.03–3.76)	0.375
	Age older than 75 years old	2.63 (0.33–20.8)	0.359	0.92 (0.31–2.75)	0.878	1.97 (0.23–17.1)	0.534
	Female	0.41 (0.14–1.23)	0.113	1.01 (0.63–1.61)	0.972	1.01 (0.33–3.08)	0.982
Second year	PV	0.54 (0.13–2.25)	0.397	0.65 (0.26–1.59)	0.342	0.99 (0.28–3.51)	0.987
	PV	0.47 (0.11–2.05)	0.314	0.64 (0.25–1.64)	0.351	1.03 (0.26–3.98)	0.969
	Age older than 55 years old	N.A.	N.A.	1.11 (0.11–10.76)	0.93	1.36 (0.12–14.97)	0.800
	Age older than 65 years old	0.31 (0.31–3.05)	0.315	1.46 (0.18–12.1)	0.725	0.36 (0.03–4.29)	0.418
	Age older than 75 years old	0.60 (0.61–5.77)	0.655	0.81 (0.09–7.73)	0.857	1.09 (0.11–10.78)	0.939
	Female	0.22 (0.27–1.84)	0.163	1.18 (0.47–2.99)	0.72	1.18 (0.32–4.37)	0.797

N.A.: not applicable, PV: pneumococcal polysaccharide vaccine, CI: confidence interval.



**Fig. 3.** Kaplan–Meier survival curve for patients with chronic obstructive pulmonary diseases (COPD) showing the proportion of subjects free from infectious acute exacerbation between PV+IV group and IV group during the follow-up period.

Kaplan–Meier survival curves for infectious acute exacerbation demonstrated a significant difference between the two groups ( $P=0.041$ , Fig. 3), while no significant difference was found in the Kaplan–Meier survival curves for pneumonia ( $P=0.543$ ) or non-infectious acute exacerbation ( $P=0.426$ ) in COPD patients (data not shown).

While neither a univariate nor multivariate analysis demonstrated a significant association between any variables and the probability of either pneumonia or non-infectious acute exacerbation in either the first or second year, a significant association between the receipt of PV and a low probability of infectious acute exacerbation was found in patients with CLD in the first year, but not in the second year by a single variable analysis ( $P=0.019$ ) or multivariate analyses ( $P=0.016$ , Table 3). No significant association was demonstrated between any variable, such as age older than 55 years, age older than 65 years, age older than 75 years or the female sex and the probability for infectious acute exacerbation, in either the first or second year.

The GMCs of serotype-specific IgG for four serotypes in sera from the 35 patients with CLD during the 2 years after their vaccinations are shown in Table 4. Before vaccination, the GMCs ranged from 2.6  $\mu\text{g/ml}$  for serotype 23F to 5.69  $\mu\text{g/ml}$  for serotype 14. One month after vaccination, significant increases in the GMCs of serotype-specific IgG were found for all serotypes in all subjects, compared to those before vaccination ( $P<0.01$ , Table 4). The GMCs of serotype-specific IgG declined below pre-vaccination levels at 6 months post-vaccination for types 6B and 19F. In contrast, the GMCs of serotype-specific IgG remained above the pre-vaccination levels for type 23F and type 14 at 2 years post-vaccination, although they had declined from the immediate post-vaccine levels. Serotype-

**Table 4**  
Serotype-specific IgG in sera from 35 patients with chronic lung diseases before 1 month, 6 months, 1 year and 2 years after vaccination

Serotype	Time point	GMC of IgG ( $\mu\text{g/ml}$ ) (95% CI)
6B	Pre	3.46(2.51–4.76)
	1 month	5.26(3.78–7.54) <sup>*</sup>
	6 months	3.51(2.48–5.1)
	1 year	3.41(2.48–4.85)
	2 year	2.68(1.86–3.97)
14	Pre	5.69(4.44–7.03)
	1 month	12.63(8.76–16.61) <sup>*</sup>
	6 months	10.35(7.17–13.6) <sup>*</sup>
	1 year	8.97(6.36–11.47) <sup>*</sup>
	2 year	7.76(5.53–10.07) <sup>*</sup>
19F	Pre	4.91(3.67–6.55)
	1 month	7.05(5.37–9.3) <sup>*</sup>
	6 months	4.81(3.56–6.49)
	1 year	4.60(3.56–5.93)
	2 year	4.58(3.46–6.05)
23F	Pre	2.60(1.97–3.42)
	1 month	5.82(3.71–9.12) <sup>*</sup>
	6 months	4.06(2.72–6.05) <sup>*</sup>
	1 year	3.56(2.48–5.1) <sup>*</sup>
	2 year	2.8(1.9–4.1)

GMC: geometric mean concentration, CI: confidence interval.

<sup>\*</sup>  $P < 0.01$  (for comparison with pre-vaccination value).

specific IgG responses to PV, therefore, were found primarily in sera during the first year, but not during the second year, following vaccination.

#### 4. Discussion

This study demonstrated an additive effect of PV with IV in preventing infectious acute exacerbation, but not pneumonia or non-infectious acute exacerbation, when compared to IV alone in patients with CLD. When these subjects were divided into three subgroups according to their type of CLD, an additive effect of PV with IV in preventing infectious acute exacerbation was found only in COPD patients, but not in patients with SPTB or other pulmonary diseases. Since no attempt was made to blind the clinical assessors to the vaccine allocation in this study, the possibility of the bias on the clinical assessment obtained by the investigators can not be dismissed.

Although this was an open-label, randomized controlled study on a small scale, the enrolled patients with CLD in this study were at a high risk for pneumonia or acute exacerbation. Since pneumococci has a major role in the development of pneumonia associated with respiratory viruses such as influenza virus, these viruses contribute to the pathogenesis of bacterial pneumonia among children [29]. Other investigators have also demonstrated that influenza neuraminidase facilitated bacterial adherence of *S. pneumoniae*, and resulted in secondary bacterial pneumonia in mice [30,31]. Based on the interaction between influenza virus and pneumococci on the pathogenesis of bacterial pneumonia, an additive or synergistic effect of the combined vaccination with PV and IV in preventing pneumococcal pneumonia can be expected.

A large prospective study in Sweden reported the additive effects of PV with IV in reducing pneumococcal pneumonia as well as invasive pneumococcal diseases, compared to no vaccination, among adults aged 65 years or older during the first 6 months after vaccination [32]. The authors demonstrated the additive effect of PV with IV only in reducing the hospital mortality due to pneumonia, compared to a vaccination with IV alone or PV alone, at 1-year after vaccination [20]. Another investigator, however, did

not find an additive effect of PV with IV in preventing pneumococcal pneumonia as well as pneumonia, compared to IV alone, among the same population during a 2-year period after vaccination [33].

A double-blind, randomized placebo-controlled trial in Thailand recently reported that IV was found highly effective in preventing the influenza-related acute respiratory illness, but not acute exacerbation or pneumonia, in COPD patients [23]. Since no effect of IV was found for preventing acute exacerbation among patients with COPD, our data suggests not only the importance of PV in addition to IV among patients with CLD, but also the role of pneumococcal infection in the pathogenesis of acute exacerbation in such patients.

Although no significant difference was found in the number of patients with pneumococcal acute exacerbation between the two groups in this study, a reduced number of pneumococcal infections in the PV+IV group may suggest the contribution of protective immunity raised by PV in such patients. More importantly, the additive effect of PV with IV on infectious acute exacerbation was significant during the first year, but not the second year after vaccination. This effect was associated with an immune response of serotype-specific IgG to PV, which was prominent in all serotypes during the first year.

Although the protective concentrations of serotype-specific IgG are not known, most of CLD patients showed a level of IgG much higher than the threshold (0.35  $\mu\text{g/ml}$ ) that predicts protection in infants against invasive disease at a population level after immunization with pneumococcal conjugate vaccine in this study [34]. A recent study also reported that higher levels of anti-pneumococcal antibodies did not correlate with protection from pneumococcal colonization in patients with COPD [35]. Therefore, the question arises as to why an additional increase of IgG in sera is required for preventing infectious acute exacerbation in COPD patients. A recent report demonstrated that the levels of anti-serotype-1 IgG in bronchoalveolar lavage (BAL) fluid were less than 10 ng/ml in 25 of 49 HIV-uninfected adults, while the mean level of serotype-1 specific IgG in sera of such subjects was 1608 ng/ml [36]. Thus, the level of specific IgG in the neat BAL fluid is at least 161 times lower than that in sera. According to this information and the data of levels of specific IgG in sera of patients with CLD before (2.60–5.69  $\mu\text{g/ml}$ ) and after vaccination (5.26–12.63  $\mu\text{g/ml}$ ) in this study, the levels of specific IgG in BAL fluid are estimated to be less than 35.3 ng/ml before vaccination and less than 78.5 ng/ml after vaccination, respectively. Since we found a significant effect of PV+IV on infectious acute exacerbation, compared with IV alone, the levels of serotype-specific IgG that rise higher than approximately 35 ng/ml in the lower airway fluid may be critical for preventing infectious acute exacerbation in patients with COPD.

Furthermore, the cost of acute exacerbation on patients with COPD creates a significant economic impact [3]. The literatures reports that the estimated costs for hospitalization due to acute exacerbation will range from \$5655 to \$7413 in developed countries [37–39]. The reduced frequency (27.2%) of acute exacerbation in the PV+IV group in this study, compared to the IV group, has significant economic implications for patients with COPD.

In conclusion, this pilot study demonstrated an additive effect of PV in combination with IV on infectious acute exacerbation of patients with COPD. This effect was closely associated with serotype-specific immune response to PV that was primarily found during the first year after vaccination. Further studies on a larger scale are required to investigate the additive effects of PV and IV on the incidence of acute exacerbation in COPD patients with various levels of airflow limitations.

## Acknowledgments


This study was supported by a Research Grant "Studies on preventable vaccines for varicella, mumps, and pneumococcal pneumonia and other diseases" for Science and Welfare, Ministry of Health, Labor and Welfare, Japan.

We are grateful to Naoko Kitajima, Miki Magome for technical assistance and the members of Pneumococcal Vaccine Trialist Group in the Kyushu and Okinawa districts: Yoshiaki Tao, National Fukuoka-Higashi Medical Center; Nobuhiro Kamikawaji, Fukuoka National Hospital; Yoshiya Kitahara, National Omuta Hospital; Toshiyuki Oe, National Saga-Higashi Hospital; Kenji Kawakami, Nagasaki Medical Center of Neurology; Kenji Higashi, National Kumamoto South Hospital; Mineharu Sugimoto, National Kumamoto Saishunso Hospital; Tatsuya Otsu, National Nishibeppu Hospital; Ryosuke, Kamitoku, National Miyazaki Hospital; Toshihiko Ii, National Miyazaki-Higashi Hospital; Fumiyuki Iwami, National Minami-Kyushu Hospital; Shigeru Miyagi, National Okinawa Hospital.

## References

- White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6. The aetiology of exacerbations of chronic obstructive pulmonary disease. *Thorax* 2003;58:73–80.
- Shishido H, Nagai H, Kurashima A, Yoneda R, Taniguchi M, Nagatake T, et al. Tuberculosis sequelae: secondary bacterial infection. *Kekkaku* 1990;65:873–80.
- Mannino DM, Brown C, Glovivo GA. Obstructive lung diseases deaths in the United States from 1979 through 1993. *Am J Respir Crit Care Med* 1997;156:814–8.
- Ruiz M, Ewig S, Macos A, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *Am J Respir Crit Care Med* 1999;160:397–405.
- Oishi K, Yoshimine H, Watanabe H, Watanabe K, Tanimura S, Kawakami K, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. *Respirology* 2006;11:429–36.
- Sethi S. New developments in the pathogenesis of acute exacerbation of chronic obstructive pulmonary disease. *Curr Opin Infect Dis* 2004;17:113–9.
- Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002;347:465–71.
- Rohde G, Wiethege A, Borg I, Kanth M, Bauer TT, Gillissen A, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary diseases requiring hospitalization: a case-control study. *Thorax* 2003;58:37–42.
- Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary diseases. *Am J Respir Crit Care Med* 2000;162:167–73.
- Musher DM, Chapman AJ, Goree A, Jonsson S, Bries D, Baughn RE. Natural and vaccine-related immunity to *Streptococcus pneumoniae*. *J Infect Dis* 1986;154:245–56.
- Butler JC, Shapiro ED, Carlone GM. Pneumococcal vaccines: history, current status, and future directions. *Am J Med* 1999;107(1A):695–765.
- Center for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). *MMWR* 1997; 46:1–24.
- Shapiro ED, Berg AT, Austrian R, Shroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. *N Engl J Med* 1991;325:1453–60.
- Davis LA, Aranda CAP, Schiffman G, Christianson CL. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. *Chest* 1987;92:204–12.
- Simberloff MS, Cross AP, Al-Ibrahim M, Balth AL, Geiseler RJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986;315:1318–27.
- Williams Jr JH, Moser KM. Pneumococcal vaccine and patients with chronic lung diseases. *Ann Intern Med* 1986;104:106–9.
- Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. *Thorax* 2006;61:189–95.
- Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. *Arch Intern Med* 1999;159:2437–42.
- Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. *Vaccine* 1999;17:591–3.
- Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. *Eur Respir J* 2004;23:363–8.
- Yoshimine H, Oishi K, Kubiru F, Nalwoga H, Takahashi H, Amano H, et al. Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia. *Am J Trop Med Hyg* 2001;64:172–7.
- Anthonsen NR, Manfreda J, Warren CP, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196–204.
- Wongsturakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness inpatients with COPD and the effectiveness of influenza vaccine. A randomized controlled study. *Chest* 2004;125:2011–20.
- WHO Pneumococcal Serology Reference Laboratories. Training manual for enzyme linked immunosorbent assay for quantitation of *Streptococcus pneumoniae* serotype specific IgG (Pn PS ELISA). 9 June, 2004 World Health Organization, Geneva, Switzerland. <http://www.vaccine.uab.edu/ELISA%20Protocol.pdf>.
- Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide enzyme absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. *Clin Diagn Lab Immunol* 2001;8:266–72.
- Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG, for the active bacterial core surveillance/emerging infections Program Network. 2005. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. *Clin Infect Dis* 2005;41:481–7.
- Dewan NA, Rafique S, Kanwar B, Sarpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD. Factors associated with poor treatment outcome. *Chest* 2000;117:662–71.
- Cote CG, Dordely IJ, Celli BR. Impact of COPD exacerbations on patient-centered outcome. *Chest* 2007;131:696–704.
- Madhi SA, Klugman KP. The Vaccine Trialist Group. A role for *Streptococcus pneumoniae* in virus-associated pneumonia. *Nature Med* 2004;10:811–3.
- McCullers JA, Rehg JE. Lethal synergism between influenza virus and *Streptococcus pneumoniae*: characterization of a mouse model and the role of platelet-activating factor receptor. *J Infect Dis* 2002;186:341–50.
- Poltola VT, Murli KG, McCuller JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. *J Infect Dis* 2005;192:249–57.
- Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. *Lancet* 2001;357:1081–111.
- Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia among persons aged 65 years or older. *Vaccine* 1999;17:2493–500.
- World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series No. 927, Annex 2, 2005. <http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.html>.
- Malley R, Lipsitch M, Bogaert D, Thompson CM, Hermans P, Watkins AC, et al. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary diseases. *J Infect Dis* 2007;196:928–35.
- Eagan R, Twigg HL, French N, Musaya J, Day RB, Zijistra EE, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. *Clin Infect Dis* 2007;44:1632–8.
- Motegi T, Yamada K, Kida K. Cost analysis inpatient therapy for patient with acute exacerbation of chronic obstructive pulmonary disease. *Nihon Kokyoku Gakkai Zasshi* 2006;44:787–94.
- Connors AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, Fulkerson WJ, et al. Outcome following acute exacerbation of severe chronic lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and scales of treatments). *Am J Respir Crit Care Med* 1997;154:959–67.
- Simonens S, Decramer M, De Coster S, Celis G, Laekemans G. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. *Int J Clin Pract* 2007;61:200–6.





This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults

Meng Chen<sup>a</sup>, Francis Ssali<sup>d</sup>, Maureen Mulungi<sup>a</sup>, Peter Awio<sup>d</sup>, Hiroyuki Yoshimine<sup>a</sup>, Reiki Kuroki<sup>a</sup>, Akitsugu Furumoto<sup>a</sup>, Susumu Tanimura<sup>b</sup>, Cissy Kityo<sup>d</sup>, Tsuyoshi Nagatake<sup>a</sup>, Peter Mugenyi<sup>d</sup>, Kazunori Oishi<sup>a,c,\*</sup>

<sup>a</sup> Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

<sup>b</sup> Department of Socio-environmental Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

<sup>c</sup> Laboratory for Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases,

Research Institute for Microbial Diseases, Osaka University, Japan

<sup>d</sup> Joint Clinical Research Centre, Kampala, Uganda

### ARTICLE INFO

#### Article history:

Received 3 January 2008

Received in revised form 24 June 2008

Accepted 28 June 2008

Available online 17 July 2008

#### Keywords:

Pneumococcal conjugate vaccine  
Pneumococcal polysaccharide vaccine  
Serotype-specific IgG  
Opsonophagocytic killing  
HIV-infected adults

### ABSTRACT

The levels of IgG determined by ELISA may have limited relevance in human immunodeficiency virus (HIV)-infected adults because of non-functional antibodies. 58 HIV-1-infected and 29 HIV-uninfected Ugandan adults were immunized with conjugate vaccine (CV) followed by polysaccharide vaccine (PV) after a 2-month interval, and the opsonophagocytic killing (OPK) titers against serotype 4 or 14 pneumococcal strains as well as the levels of serotype-specific IgG in sera were determined. Significant increases were found in the OPK titers and IgG levels for both serotypes after CV vaccination irrespective of HIV status. Increases in IgG levels and OPK titers were largely dependent on the CD4<sup>+</sup> cell counts, except for increases in the IgG levels for serotype 4. The proportions with serum OPK titer equal to or greater than 8 were 0–4.3% for serotype 4 and 26.7–42.9% for serotype 14 before vaccination, but the proportions increased up to 43.3–86.2% for serotype 4 and 63.3–96.6% for serotype 14 in all three groups 2 months after CV vaccination. The serum OPK titers remained at levels higher than the pre-vaccination level for at least 8 months after CV vaccination. A single dose of CV could afford some protective immunity in HIV-infected African adults before the introduction of antiretroviral therapy.

© 2008 Elsevier Ltd. All rights reserved.

### 1. Introduction

More than 60% of the 40 million people living with HIV in the world are in sub-Saharan Africa [1]. HIV infection is, therefore, a major health concern facing adults in this area. The authors' previous study of community-acquired pneumonia (CAP) among adults in Uganda revealed a high prevalence of HIV-1 infection among these patients [2]. The majority of HIV-1-infected patients with CAP have peripheral CD4 counts below  $400 \mu\text{l}^{-1}$ . *Streptococcus pneumoniae* (*S. pneumoniae*) was found to be a common pathogen, which was isolated in approximately 40% of bacterial CAP. The host defense against *S. pneumoniae* depends largely on opsonophagocytic killing antibodies to capsular polysaccharide (CPS) [3,4],

although an antibody-independent, CD4<sup>+</sup> T cell-dependent mechanism of protection has been reported in mouse model [5,6]. Low opsonic activity in the sera of HIV-infected African adults, therefore, predisposes them to a serious risk of invasive pneumococcal infections [7–9].

Approaches to prevent bacterial pneumonia in adults with HIV infection involve antimicrobial prophylaxis, highly active antiretroviral therapy (ART) and vaccination [10]. Although a significant decrease in the rates of bacterial pneumonia in HIV-infected adults after antimicrobial prophylaxis with co-trimoxazole has been reported in Cote, d'Ivoire [11], further studies are required to confirm its effects in preventing bacterial pneumonia even in areas where penicillin-resistant pneumococci are highly prevalent in the population [12]. ART can prevent bacterial pneumonia in HIV-infected adults in developed countries, but this has not been confirmed in developing countries [13]. Although the WHO recommends that HIV-infected adults and adolescents, who are either in WHO clinical staging 4 or have a CD4 cell count below  $200 \mu\text{l}^{-1}$  start

\* Corresponding author at: 3-1 Yamadaoka, Suita 565-0871, Japan.

Tel.: +81 6 6879 4253; fax: +81 6 6879 4255.

E-mail address: [oishik@biken.osaka-u.ac.jp](mailto:oishik@biken.osaka-u.ac.jp) (K. Oishi).

ART [1], an access to ART is limited in sub-Saharan Africa including Uganda [14]. The WHO estimates that only 20% of the estimated 6.5 million people in low and middle-income countries who are in urgent need of ART were receiving ART at the end of 2005 [15].

Previous studies reported the effects of pneumococcal polysaccharide vaccine (PV) in HIV-infected African adults [16,17]. A clinical study of PV in HIV-infected Ugandans, however, has demonstrated an increased risk of invasive pneumococcal infection and no protection against all-cause pneumonia [18], and the same group subsequently reported a 16% reduction in all-cause mortality after PV vaccination [19]. The use of PV in HIV-infected African adults is therefore inconclusive. On the other hand, previous studies in the Netherlands, US and Uganda reported promising effects of pneumococcal conjugate vaccine (CV), which induced high levels of serotype-specific IgG among HIV-infected adults [20–22]. Furthermore, an enhanced antibody response to certain serotypes has been shown in HIV-infected adults following immunization with PV after prior immunization with CV [20,23]. The concentration of serotype-specific IgG determined by ELISA, however, may have limited relevance in HIV-infected adults and children because of non-functional anti-CPS IgG [6,7,24,25]. Analysis of serum opsonophagocytic killing (OPK) activity is, therefore, required to study the immunogenicity of CV in HIV-infected adults. This study was designed to determine whether immunization with CV followed by PV could increase the levels of serotype-specific IgG and OPK titers against *S. pneumoniae* in sera of HIV-infected African adults before the introduction of ART.

## 2. Materials and methods

### 2.1. Subjects

After providing written informed consent, HIV-1-infected and HIV-uninfected asymptomatic adults were enrolled by two physicians at the Joint Clinical Research Centre (JCRC), Kampala between February and June 2005. HIV-1 infection was determined by a screening EIA (HIV1&2 Rapid Serotest, Healthcare Technologies Ltd., Ashdod, Israel) and a second EIA for confirmation (Vironostika HIV Uni-Form II Ag/Ab, bioMérieux, Marcy l'Etoile, France). Study subjects were classified into three subgroups: group I (HIV-1-infected adults with peripheral CD4<sup>+</sup> cell count: 200–499  $\mu\text{l}^{-1}$ ;  $n=30$ ), group II (HIV-1-infected adults with peripheral CD4<sup>+</sup> cell count:  $\geq 500 \mu\text{l}^{-1}$ ;  $n=28$ ) and group III (HIV-uninfected adults;  $n=29$ ) (Table 1). Plasma HIV-1 RNA loads were quantified as described elsewhere for the total of 58 HIV-infected adults [26]. Enrolling 90 subjects in three study groups would have given the study 70% power at an alpha level of 0.05 to detect a significant increase in the percentage of persons responding with a  $\geq 2$ -fold rise in the serum levels of serotype-specific IgG from 42% to 74% between groups of HIV-infected and HIV-uninfected adults [27].

### 2.2. Immunization of study subjects with pneumococcal vaccines

Seven-valent CV (Prevenar<sup>®</sup>, Wyeth-Lederle), containing 2  $\mu\text{g}$  of six serotypes (4, 9V, 14, 18C, 19F and 23F) and 4  $\mu\text{g}$  of CPS from 6B covalently linked to a CRM<sub>197</sub>, non-toxic mutant diphtheria toxin, was given as an intradeltoid injection to all of the study subjects. Two months after CV vaccination, 23-valent PV (Pneumovax, Merck-Banyu), which contains 25  $\mu\text{g}$  of each of 23 serotypes was given as an intradeltoid injection to all of the study subjects. All of the study subjects were requested to visit the outpatient department of JCRC, and be examined by two physicians immediately before and 2, 3 and 8 months after CV vaccination. Serum samples were also obtained at the time of the scheduled visits throughout the study, and stored at  $-80^\circ\text{C}$  until use. When they had new symptoms, the participants were asked to visit the outpatient department of the JCRC for medical examination by the physicians. At 8 months post-CV vaccination, the peripheral CD4<sup>+</sup> cell count was reexamined in HIV-infected adults. While all of HIV-infected subjects were successfully followed for the study period, six of the HIV-uninfected healthy control subjects were lost by the time of follow-up. Sera were subsequently collected from 23 HIV-uninfected subjects 8 months after CV vaccination.

### 2.3. Determination of serotype-specific IgG levels

Since preabsorption of serum with both cell wall polysaccharide (PS) and 22F PS is necessary to remove non-specific antibodies in HIV-infected adults and HIV-uninfected adults, the concentrations of serotype-specific IgG were measured using the US reference pneumococcal antiserum (89 SF-3), courtesy of Dr. Carl Frasch, as previously described [28,29]. Among 29 pneumococcal isolates known as etiologic agents of CAP in Ugandan adults [2], 5 strains of serotype 4 and 3 strains of serotype 14 were identified (unpublished data). Therefore, we decided to use ELISA to determine the IgG levels in sera for serotypes 4 and 14 CPS, which are major serotypes in Uganda.

### 2.4. Differentiation of HL-60 cells and OPK assay

Undifferentiated HL-60 cells (Cell number: JCRB0085, Health Science Research Resources Bank, Japan) were cultured in RPMI-1640 medium with 10% fetal calf serum (FCS) (Hyclone, South Logan, UT). HL-60 cells were differentiated into granulocytes in the presence of 1  $\mu\text{M}$  all-trans-retinoic acid (Sigma Chemical Co., St. Louis, MO) in RPMI-1640 medium with 20% FCS for 3 days [30,31]. Cells were washed twice by centrifugation, and the supernatant was removed. 20  $\mu\text{l}$  of PE-conjugated mouse anti-human CD11b monoclonal IgG<sub>1</sub> (BD PharMingen, San Diego, CA) or PE-conjugated mouse monoclonal IgG<sub>1</sub> isotype control (Dakocytomation AS, Glostrup, Denmark) were added to each tube and incubated at  $4^\circ\text{C}$  for 30 min. Samples were washed twice and resuspended in PBS containing 1% paraformaldehyde, and analyzed by flow cytometry.

**Table 1**  
Clinical characteristics and laboratory data for 58 HIV-1-infected and 29 HIV-uninfected adults

Characteristic	Time point	Group I ( $n=30$ ) HIV-1*, CD4: 200–499 $\mu\text{l}^{-1}$	Group II ( $n=28$ ) HIV-1*, CD4: $\geq 500 \mu\text{l}^{-1}$	Group III ( $n=29$ ) HIV-1*
Age, mean years $\pm$ S.D.	Pre	36.77 $\pm$ 7.45 <sup>a</sup>	37.11 $\pm$ 7.63 <sup>a</sup>	26.83 $\pm$ 7.70
Peripheral CD4 <sup>+</sup> cell count, mean cell/ $\mu\text{l}$ $\pm$ S.D.	Pre	352.00 $\pm$ 80.71 <sup>a,b</sup>	720.25 $\pm$ 170.69 <sup>c</sup>	882.45 $\pm$ 257.45
log <sub>10</sub> plasma HIV RNA load copies/ml $\pm$ S.D.	Pre	4.81 $\pm$ 0.85 <sup>b</sup>	3.84 $\pm$ 0.83	ND
Peripheral CD4 <sup>+</sup> cell count, mean cell/ $\mu\text{l}$ $\pm$ S.D.	8 m post-CV	362.41 $\pm$ 155.82 <sup>b</sup>	707.39 $\pm$ 213.79	ND

ND: Not done.

<sup>a</sup>  $P < 0.001$  (vs. group III).

<sup>b</sup>  $P < 0.001$  (vs. group II).

<sup>c</sup>  $P < 0.01$  (vs. group III).

(FACSCalibur, BD Biosciences, San Jose, CA). While no expression of CD11b was found in the undifferentiated cells, increased expression of CD11b was found in the differentiated cells by retinoic acid (data not shown). The expression of CD11b was specific because no increase was found in the fluorescent intensity of the differentiated cells stained with PE-conjugated control antibody.

OPK titer against *S. pneumoniae* was measured as described elsewhere with some modification [32]. Briefly, the differentiated HL-60 cells were used as an effector/target cell ratio of 400/1. 10  $\mu$ l of serially diluted serum sample was aliquoted into each well of 96-well microtiter plate. *S. pneumoniae* serotype 4 (strain P-03-106) or serotype 14 (strain P-03-170), both isolated from patients with CAP, were used for this assay. In addition, we also employed two reference strains (DS2382-94 for serotype 4 and DS2214-94 for serotype 14) as standard quality control strains for this assay [32]. These reference strains were gifts from Dr. Moon H. Nahm, University of Alabama at Birmingham. 20  $\mu$ l of bacterial suspension ( $\sim 10^3$  cfu) was added to each well. Then the plate was allowed to incubate at 37 °C in a 5% CO<sub>2</sub> atmosphere for 15 min. Following this incubation period, 10  $\mu$ l of rabbit complement (DynaL Biotech Inc., Lake Success, NY) was added to each well. Then, 40  $\mu$ l of washed cells ( $4 \times 10^5$  cells) was immediately added to each well. The assay plate was incubated at 37 °C for 45 min with horizontal shaking (220 rpm). A 5  $\mu$ l aliquot from each well was plated onto an agar medium plate. Plates were incubated overnight and viable colonies were counted for each well. Typically, 10–60 colonies were counted. The OPK titers were expressed as the reciprocal of the serum dilution with  $\geq 50\%$  killing compared with the growth in the complement control wells. Serum samples with titers of  $< 8$  were reported as a titer of 4 for analysis of the levels of serotype-specific IgG, but excluded for analysis of the correlation between the levels of IgG or HIV-1 viral load and the serum OPK titers. Quality control sera (sera with a known titer) were added to each plate and the blinded test samples for OPK titer were examined only when the titers of quality control sera were identical. Functional activity of serotype-specific IgG was expressed as a concentration of IgG required for 50% killing of pneumococcal strain by dividing the IgG concentration of a test sample by OPK titer.

### 2.5. Statistical analysis

The subjects' ages, CD4<sup>+</sup> cell count and levels of HIV-1 viral load were compared by one-way analysis of variance and by multiple comparison methods. Differences in geometric mean concentrations (GMCs) of serotype-specific IgG, OPK titers and the ratios of OPK titer to serotype-specific IgG were assessed using the Friedman and Steel-Dwass tests [33]. The significance of the correlation was

estimated using Spearman's rank correlation. Data were considered significant when  $P < 0.05$ .

### 3. Results

No difference was found in age between groups I and II, but differences in age were significant between either of group I or II and the group III ( $P < 0.001$ , Table 1). Differences in CD4<sup>+</sup> cell count and the level of HIV-1 viral load were significant between groups I and II ( $P < 0.001$ ), which is in agreement with our previous report [26]. No significant decrease in the CD4<sup>+</sup> cell count was found in either group I or II during the 8 months post-CV vaccination. ART was initiated in one case (32 years old, male) in the group I at 7 months post-CV vaccination because of recurrent pneumonia. The CD4<sup>+</sup> cell count and plasma log<sub>10</sub> HIV viral load of this case were 212  $\mu$ l<sup>-1</sup> and 5.78, respectively, at the time of enrollment.

No significant difference was found in the GMCs of IgG specific to either serotype 4 or 14 in sera among the three groups before vaccination (Table 2). Two months after CV vaccination, significant increases in the GMCs of IgG specific to both serotypes 4 and 14 were found for all three groups, compared to those before vaccination ( $P < 0.01$ ).

No significant difference was found in the GMCs of IgG specific to serotype 4 among the three groups 2 months after CV vaccination ( $P = 0.23$ ). In contrast, the GMCs of IgG specific for serotype 14 were highest in group III, followed by group II, with group I having the lowest GMC 2 months after CV vaccination, and the difference between groups I and III was significant at this time point ( $P < 0.05$ ). One month post-vaccination with PV (3 months after CV vaccination), however, no significant increase was found in the GMCs of IgG specific to either serotype 4 or 14 compared to those at 2 months after vaccination with CV in each group. Although the GMCs of IgG specific to serotype 14 largely declined at 8 months post-vaccination with CV, no significant decrease in the GMCs of IgG specific to serotypes 4 was found in any group between 2 months after CV vaccination and 8 months after CV vaccination. The GMCs of IgG specific to both serotypes 4 and 14 were still higher 8 months after CV vaccination than before vaccination. In addition, no correlation was found between the fold increase of specific IgG to either serotype 4 or 14 after CV vaccination and the levels of HIV-1 viral load in HIV-infected adults.

The concentration of 0.35  $\mu$ g/ml for serotype-specific IgG has been suggested by world health organization (WHO) working group as a putative measure of protection against invasive disease in infants at a population level after immunization with pneumococcal conjugate vaccine [34]. This working group reported that antibody concentrations of 0.2–0.35  $\mu$ g/ml correlated best with an

**Table 2**  
Comparison of geometric mean concentrations of serotype-specific IgG in sera from HIV-1-infected patients and HIV-uninfected adults before vaccination and after vaccination

Serotype	Time point	GMC of IgG ( $\mu$ g/ml) (95% CI) in sera from		
		Group I (n=30) HIV-1*, CD4: 200–499 $\mu$ l <sup>-1</sup>	Group II (n=28) HIV-1*, CD4: $\geq 500$ $\mu$ l <sup>-1</sup>	Group III (n=29) HIV-1*
4	Pre	1.55 (1.15–2.08)	0.82 (0.58–1.18)	0.83 (0.59–1.16)
	2 m post-CV	4.17 (3.03–5.73) <sup>a</sup>	4 (2.78–5.74) <sup>a</sup>	6.75 (4.78–9.52) <sup>a</sup>
	3 m post-CV (1 m post-PV)	4.56 (3.51–5.92) <sup>a</sup>	3.88 (2.73–5.52) <sup>a</sup>	6.87 (4.89–9.66) <sup>a</sup>
	8 m post-CV	5.52 (4.41–6.9) <sup>a</sup>	4.07 (3.19–5.19) <sup>a</sup>	4.64 (3.60–5.98) <sup>a,d</sup>
14	Pre	5.27 (3.76–7.37)	5.1 (3.40–7.66)	4.67 (2.75–7.94)
	2 m post-CV	25.31 (16.79–38.14) <sup>a,b</sup>	42.44 (23.41–76.95) <sup>a</sup>	52.11 (31.41–86.45) <sup>a</sup>
	3 m post-CV (1 m post-PV)	23.14 (15.96–33.55) <sup>a,c</sup>	42.76 (23.98–76.24) <sup>a</sup>	53.86 (34.11–85.05) <sup>a</sup>
	8 m post-CV	17.73 (12.68–24.79) <sup>a,c</sup>	28.66 (17.18–47.81) <sup>a</sup>	37.8 (24.99–57.18) <sup>a,d</sup>

CI: Confidence interval; Pre: pre-vaccination; CV: pneumococcal conjugate vaccine; PV: pneumococcal polysaccharide vaccine.

<sup>a</sup>  $P < 0.01$  (vs. pre-vaccination).

<sup>b</sup>  $P < 0.05$  (vs. group III).

<sup>c</sup>  $P < 0.01$  (vs. group III).

<sup>d</sup> n = 23 in group III.

OPK titer of 8 [34], which in turn correlated best with protective efficacy in infants. The proportions of subjects with IgG specific to serotype 4 of  $\geq 0.35 \mu\text{g/ml}$  were 100% in group I, 85.7% in group II and 79.3% in group III before vaccination and 100% for all groups 2 months after CV vaccination in this study. The proportions of subjects with IgG specific to serotype 14 of  $\geq 0.35 \mu\text{g/ml}$  were 100% in groups I and II and 96.4% in the group III, before vaccination and 100% for all groups 2 months after CV vaccination.

The geometric means of serum OPK titers for the serotypes 4 and 14 were similarly low in sera of all three groups before vaccination (Table 3). The differences among the three groups were not statistically significant. Two months after CV vaccination, significant increases in the serum OPK titers for both serotype strains 4 and 14 compared to pre-vaccination levels were found in all three groups ( $P < 0.01$ ). The serum OPK titers for both serotypes 4 and 14 were highest in group III followed by group II, with group I having the lowest titers 2 months after CV vaccination. Serum OPK titers for both serotypes 4 and 14 differed significantly between groups I and III at 2, 3 and 8 months after vaccination with CV ( $P < 0.01$ ). Group II had significantly higher OPK titers than group I for serotype 4 at 3 and 8 months post-vaccination with CV, and for serotype 14 at 8 months post-vaccination with CV ( $P < 0.05$ ). In additional experiments, the OPK titers of nine serum samples (three from each group) were determined using strains of DS2382-94 and DS2214-94 which are widely used as target strains for serotypes 4 and 14, respectively. The values of serum OPK titer were identical or close to those determined using the non-reference strains (data not shown).

The proportions of subjects with a serum OPK titer of  $\geq 8$  were very low (0–4.3%) for serotype 4 in all three groups before vaccination (Fig. 1). On the other hand, the proportion was lower in group I (26.7%) than those in group II (42.9%) or group III (41.4%) for serotype 14 before vaccination. In contrast, marked increases in the proportion with a serum OPK titer of  $\geq 8$  were found for both serotypes in all three groups two months after CV vaccination. The proportion of the serum OPK titer of  $\geq 8$  was highest in group III, followed by group II and group I for both serotypes at 2 and 3 months post-CV vaccination. Eight months after CV vaccination, the proportions of subjects with a serum OPK titer of  $\geq 8$  decreased in groups I and II for both serotypes.

Since few serum samples contained detectable OPK titers for serotype 4 before vaccination (one in group I, none in group II and three in group III), correlations were not assessed between the levels of serotype-specific IgG and the serum OPK titers. On




Fig. 1. The proportion of subjects with opsonophagocytic killing (OPK) titers equal to or greater than 8 for serotype 4 (upper panel) and serotype 14 (lower panel) in groups I ( $n = 30$ , closed bar), II ( $n = 28$ , grey bar), and III ( $n = 29$ , open bar) before and 2, 3 and 8 months after vaccination with pneumococcal conjugate vaccine (CV). \*  $n = 23$  in group III at 8 months after CV vaccination.

the other hand, the concentrations of serotype-specific IgG significantly correlated with OPK titers for serotype 14 before vaccination in groups II ( $r = 0.61$ ,  $P < 0.05$ ,  $n = 14$ ) and III ( $r = 0.61$ ,  $P < 0.05$ ), but not in group I ( $r = 0.56$ ,  $P = 0.08$ ,  $n = 11$ ). Two months after CV vaccination, significant correlations between two parameters were found for serotype 4 in groups I ( $r = 0.74$ ,  $P < 0.01$ ,  $n = 15$ ) and III ( $r = 0.67$ ,  $P < 0.001$ ,  $n = 26$ ), but not in group II ( $r = 0.27$ ,  $P = 0.2$ ,  $n = 23$ ) and for serotype 14 in groups II ( $r = 0.85$ ,  $P < 0.001$ ,  $n = 23$ ) and III ( $r = 0.38$ ,  $P = 0.05$ ,  $n = 28$ ), but not in group I ( $r = 0.44$ ,  $P = 0.06$ ,  $n = 11$ ).

The GMCs of serotype-specific IgG required for 50% killing ranged 136–601 ng/ml in the group I, 79–377 ng/ml in the group II and 72–316 ng/ml in the group III, although few data are available for serotype 4-specific IgG before vaccination (Table 4). No

Table 3  
Comparison of geometric mean opsonophagocytic killing (OPK) titers of sera from HIV-1-infected and HIV-uninfected adults before vaccination and after vaccination

Serotype	Time point	GM OPK titer (95% CI) of sera from		
		Group I ( $n = 30$ ) HIV-1*, CD4: 200–499 $\mu\text{l}^{-1}$	Group II ( $n = 28$ ) HIV-1*, CD4: $\geq 500 \mu\text{l}^{-1}$	Group III ( $n = 29$ ) HIV-1*
4	Pre	4.29 (3.72–4.94)	4 (4–4)	4.62 (3.76–5.66)
	2 m post-CV	13.93 (7.78–24.94) <sup>a,b</sup>	32 (19.08–53.68) <sup>a,c</sup>	75.66 (45.15–126.77) <sup>a</sup>
	3 m post-CV (1 m post-PV)	13.61 (7.91–23.41) <sup>a,b,e</sup>	37.12 (22.21–62.07) <sup>a</sup>	73.87 (45.71–119.36) <sup>a</sup>
	8 m post-CV	6.81 (4.61–10.04) <sup>b,d,e</sup>	18.11 (10.18–32.22) <sup>a</sup>	44.58 (26.55–74.84) <sup>a,f</sup>
14	Pre	7.29 (5.10–10.43)	12.8 (7.52–21.82)	12.01 (6.94–20.78)
	2 m post-CV	41.26 (19.57–87.01) <sup>a,c</sup>	107.63 (51.49–225.02) <sup>a</sup>	275.03 (173.88–435.03) <sup>a</sup>
	3 m post-CV (1 m post-PV)	43.21 (20.42–91.46) <sup>a,b</sup>	118.84 (57.32–246.38) <sup>a</sup>	281.68 (181.69–436.72) <sup>a</sup>
	8 m post-CV	13.61 (7.62–24.3) <sup>b,e</sup>	47.55 (22.52–100.42) <sup>a</sup>	116.94 (69.96–195.45) <sup>a,f,g</sup>

CI: Confidence interval; Pre: pre-vaccination; CV: pneumococcal conjugate vaccine; PV: pneumococcal polysaccharide vaccine.

<sup>a</sup>  $P < 0.01$  (vs. pre-vaccination).

<sup>b</sup>  $P < 0.01$  (vs. group III).

<sup>c</sup>  $P < 0.05$  (vs. group III).

<sup>d</sup>  $P < 0.05$  (vs. pre-vaccination).

<sup>e</sup>  $P < 0.05$  (vs. group II).

<sup>f</sup>  $P < 0.05$  (vs. 2 and 3 months post-CV).

<sup>g</sup>  $n = 23$  in group III.

**Table 4**  
Comparison of geometric mean concentration (GMC) of serotype-specific IgG required for 50% killing (OPK) titers of sera from HIV-1-infected and HIV-uninfected adults before vaccination and after vaccination

Serotype	Time point	GMC of IgG (ng/ml) required for 50% killing (95% CI) [no. of subjects evaluated] in sera from		
		Group I (n = 30) HIV-1*, CD4: 200–499 $\mu\text{l}^{-1}$	Group II (n = 28) HIV-1*, CD4: $\geq 500 \mu\text{l}^{-1}$	Group III (n = 29) HIV-1
4	Pre	284 (NA) [1]	NA (NA)	179 (9–3492) [3]
	2 m post-CV	136 (80–234) [14]	102 (68–155) [23]	72 (52–100) [26]
	3 m post-CV (1 m post-PV)	137 (80–234) [15]	79 (56–111) [23]	76 (55–106) [26]
	8 m post-CV	201 (57–706) [7]	86 (46–161) [16]	96 (56–163) [22] <sup>a</sup>
14	Pre	441 (236–825) [11]	248 (139–441) [14]	307 (149–631) [15]
	2 m post-CV	302 (182–501) [19]	279 (204–382) [23]	176 (101–305) [28]
	3 m post-CV (1 m post-PV)	229 (142–372) [19]	246 (163–369) [23]	174 (106–288) [28]
	8 m post-CV	601 (364–992) [14] <sup>b</sup>	377 (269–529) [18]	316 (207–481) [22] <sup>a</sup>

CI: Confidence interval; Pre: pre-vaccination; CV: pneumococcal conjugate vaccine; PV: pneumococcal polysaccharide vaccine; NA: not available.

<sup>a</sup> n = 23 in group III.

<sup>b</sup> P < 0.05 (vs. 3 m post-CV).

significant difference was found in the GMCs of serotype-specific IgG required for 50% killing in sera among the three groups before and after vaccination. No significant difference was also found in the GMCs of serotype-specific IgG required for 50% killing of each group among different time points, with a exception of a significant difference in those of group I between 3 months after CV vaccination and 8 months after CV vaccination ( $P < 0.05$ ). No significant effect of vaccination with PV following CV was found in the serum OPK titers for either serotype 4 or 14 in any group. Eight months after CV vaccination, the serum OPK titers for serotypes 4 and 14 largely declined compared to those 2 months after CV vaccination. The OPK titers for serotypes 4 and 14 in sera of the three groups, however, remained higher than pre-vaccination levels at 8 months post-vaccination with CV. In addition, no correlation was found between the increase in serum OPK titers for both serotypes 4 and 14 after CV vaccination and the levels of HIV-1 viral load in HIV-infected adults.

#### 4. Discussion

In this study, it has been demonstrated that a single dose of CV can increase serum OPK titers against pneumococcal strains as well as the levels of serotype-specific IgG, in HIV-uninfected and HIV-infected Ugandan adults with peripheral CD4<sup>+</sup> cell counts of  $\geq 200 \mu\text{l}^{-1}$  for at least 8 months after CV vaccination. HIV-infected adults with peripheral CD4<sup>+</sup> cell counts less than  $200 \mu\text{l}^{-1}$  who were at risk for pneumococcal infections were not involved in this study, because they are recommended to receive ART [1] and are known to be poorly responsive to CV [20,27]. Serotype 14-specific IgG response to a single dose of CV was dependent on CD4<sup>+</sup> cell counts in HIV-infected adults, which was in agreement with previous reports [20,22], but the magnitude of IgG response to CV in our study was higher than that shown in a previous study [22]. In contrast, serotype 4-specific IgG response to a single dose of CV was independent of CD4<sup>+</sup> cell counts in our study; this finding was also consistent with a previous study [22].

The major limitation in this study may be the lack of an unvaccinated control group. Pneumococcal pneumonia or nasopharyngeal colonization may increase the levels of serotype-specific IgG in sera from subjects, in addition to the immunological effects by vaccination, during the study period [35]. Since only five episodes of pneumonia with unknown etiology were identified in the HIV-infected and HIV-uninfected groups (two episodes in group I, one episode in group II and two episodes in group III) during the 8 months (data not shown), we speculate that the possibility of active immunization by pneumococcal pneumonia among study participants was low in this study. Since the nasopharyngeal carriage of pneumococcal strains was not examined in this study, the influ-

ence of nasopharyngeal carriage on the levels of IgG and OPK titers in serum cannot be dismissed.

Although a previous study reported an immunological effect of a CV primed PV booster with a 4-week interval in HIV-infected adults [23], no effects of PV following CV vaccination were found in the levels of serotype 4 or 14-specific IgG in our study. The lack of additional immune response after PV following CV could be explained by the differences in races and ages of the participants and in the timing of the PV boost 2 months following CV in this study [23]. Another reason for the lack of additional immune response by PV might be the increased levels of serotype 4 or 14 specific IgG achieved by CV, because a recent study similarly demonstrated that elderly subjects with a serotype-specific IgG higher than  $5 \mu\text{g/ml}$  in sera before vaccination tended to respond to PV at a lower magnitude [36]. The undiminished persistence of the levels of OPK titers and of IgG shown in this study up to 8 months after CV vaccination may, in part, be explained by the boosting effect of nasopharyngeal carriage of pneumococcal strains [37].

The general consensus on measuring the serum OPK titers encouraged the authors to develop this assay for the evaluation of immunogenicity in this study [24]. Although an OPK assay for the measurement of functional antibody activity has been available [32], there were difficulties in achieving differentiation of HL-60 cells into granulocytes in the presence of dimethylformamide as a previous study indicated [38]. In this study, it has been shown that differentiated HL-60 cells by the use of retinoic acid can be applicable for an OPK assay against *S. pneumoniae* for evaluation of the immunogenicity of CV.

While the proportions of subjects with serotype-specific IgG of  $\geq 0.35 \mu\text{g/ml}$  were higher than 80% and 95% for serotypes 4 and 14 among HIV-infected and HIV-uninfected Ugandan adults in this study, a previous study demonstrated that the proportions of subjects with serotype-specific IgG were less than 10% for serotype 4 and less than 30% for serotype 14 among unvaccinated HIV-infected African children [25]. A relatively low proportion of subjects, however, exhibited OPK titers of  $\geq 8$  for serotypes 4 and 14 in both HIV-infected and -uninfected Ugandan adults before vaccination in this study. Although WHO working group reported that 0.2–0.35  $\mu\text{g/ml}$  for the levels of serotype-specific IgG correlate with an OPK titer of 8 in infants [34], this threshold may not be applicable for unvaccinated adults.

In this study, we determined the levels of serotype-specific IgG, but not IgM or IgA. While a poor correlation was found between the opsonic activity and the levels of either CPS-specific IgM or IgA, the serum opsonic activity correlated best with the levels of CPS-specific IgG in healthy adults following CV vaccination [39,40]. The levels of IgG significantly correlated with the OPK titers for serotype 4, except for group II, and for serotype 14, except for group I, 2

months after CV vaccination in this study. Furthermore, the GMCs of serotype-specific IgG required for 50% killing ranged 79–601 ng/ml in HIV-infected adults and 72–315 ng/ml in HIV-uninfected adults after a single dose of CV vaccination in this study. In contrast, the GMCs of serotype-specific IgG required for 50% killing ranged 2–119 ng/ml in infant populations after CV vaccination [41–43]. Collectively, our present data suggest that opsonic function of serotype-specific IgG after CV vaccination is much decreased in Ugandan adults, irrespective of HIV infection, than those in infants.

In conclusion, this study documents the immunogenicity of a single dose of CV on the OPK titer and the levels of serotype-specific IgG in sera of HIV-infected Ugandan adults with CD4<sup>+</sup> cell count higher than 200  $\mu\text{l}^{-1}$ . A single dose of CV increased the serum OPK activity as well as the levels of IgG, and maintained them above their pre-vaccination levels for at least 8 months after CV vaccination. A single dose of CV could increase protective immunity in HIV-infected African adults with CD4<sup>+</sup> cell count higher than 200  $\mu\text{l}^{-1}$  before the introduction of ART. A clinical trial of the efficacy of CV in this population is needed in sub-Saharan Africa.

### Acknowledgments

This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology in Japan and the 21st Century Center of Excellence Program of Japan and Science, and from the Ministry of Health, Labor and Welfare on "Studies on preventable vaccines for varicella, mumps, and pneumococcal and other diseases" and "Studies on evidence and strategies for the improvement of usefulness of vaccines." We are grateful to Dr. Moon H. Nahm for his critical comments on this manuscript, and Naoko Kitajima and Miki Magome for technical assistance.

### References

- [1] Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Available at: <http://www.who.int/hiv/pub/guidelines/adult/en/pdf>. Accessed, 2006.
- [2] Yoshimine H, Oishi K, Mubiru F, Nalwoga H, Takahashi H, Amano H, et al. Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia. *Am J Trop Med Hyg* 2001;64:172–7.
- [3] Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to *Streptococcus pneumoniae*. *J Infect Dis* 1986;154:245–56.
- [4] Vitharsson G, Jonsson I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of *Streptococcus pneumoniae*. *J Infect Dis* 1994;170:592–9.
- [5] Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4<sup>+</sup> T cell mediate antibody-independent acquired immunity to pneumococcal colonization. *Proc Natl Acad Sci USA* 2005;102:4848–53.
- [6] Basset A, Thompson CM, Hollingshead SK, Briles DE, Ades EW, Lipsitch M, et al. Antibody-independent, CD4<sup>+</sup> T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. *Infect Immun* 2007;75:5460–4.
- [7] Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal diseases. *Curr Opin Infect Dis* 2007;20:11–5.
- [8] Takahashi H, Oishi K, Yoshimine H, Kumatori A, Moji K, Watanabe K, et al. Decreased serum opsonic activity for *Streptococcus pneumoniae* in HIV-infected Ugandan adults. *Clin Infect Dis* 2003;37:1534–40.
- [9] Eagan R, Twigg HL, French N, Musaya J, Day RB, Zijstra EE, et al. Lung fluid immunoglobulin from HIV-infected subjects has impaired opsonic function against pneumococci. *Clin Infect Dis* 2007;44:1632–8.
- [10] Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. *Lancet Infect Dis* 2004;4:445–55.
- [11] Anglaret X, Chene G, Attia A, Toure S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomized trial. *Lancet* 1999;353:1463–8.
- [12] Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. World Health Organization. Available at [www.who.int/hiv/pub/guidelines/ctx/en/](http://www.who.int/hiv/pub/guidelines/ctx/en/). Accessed, 2006.
- [13] Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360:119–29.
- [14] Mugenyi P, Kityo C, Kibende S. Scaling up antiretroviral therapy: experience of the Joint Clinical Research Centre (JCRC) access program. *Acta Academia Suppl* 2006;1:216–40.
- [15] Progress on global access to HIV antiretroviral therapy. A report on "3 by 5" and beyond. World Health Organization. Available at: [http://www.who.int/hiv/progressreport2006\\_summary\\_en.pdf](http://www.who.int/hiv/progressreport2006_summary_en.pdf). Accessed, 2006.
- [16] Janoff EN, Fasching C, Ojoo JC, O'Brien J, Gilk CF, et al. Responsiveness of human immunodeficiency virus type 1-infected Kenyan woman with or without prior pneumococcal disease to pneumococcal vaccine. *J Infect Dis* 1997;175:975–8.
- [17] French N, Gilks CF, Mujugira A, Fashing C, O'Brien J, Janoff EN. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. *AIDS* 1998;12:1683–9.
- [18] French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet* 2000;355:2106–11.
- [19] Watera C, Nakiyingi J, Miro G, Muwonge R, Whitworth JAG, Gilks CF, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. *AIDS* 2004;18:1230–3.
- [20] Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. *Vaccine* 2001;19:886–94.
- [21] Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. *Vaccine* 2002;20:545–53.
- [22] Miro G, Kayhty H, Watera C, Tolmie H, Whitworth JAG, Gilks CF, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. *J Infect Dis* 2005;192:1801–5.
- [23] Lesprit P, Pedrono G, Molina J-M, Goujard C, Girard P, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *AIDS* 2007;21:2425–34.
- [24] Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Glodblat D, Nahm MN. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Clin Vaccine Immunol* 2006;13:165–9.
- [25] Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. *Pediatr Infect Dis J* 2005;24:410–6.
- [26] Oishi K, Hayano M, Yoshimine T, Tugume SB, Kebba A, Mugerwa R, et al. Expression of chemokine receptors on CD4<sup>+</sup> T cells in peripheral blood from HIV-infected individuals in Uganda. *J Interferon Cytokine Res* 2000;20:597–602.
- [27] Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugated pneumococcal vaccine: results from a randomized trial. *J Infect Dis* 1996;173:83–90.
- [28] Conception NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. *Clin Diagn Lab Immunol* 2001;8:266–72.
- [29] Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccine in human immunodeficiency virus-infected adults. *Clin Diagn Lab Immunol* 2004;11:137–41.
- [30] Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc Natl Acad Sci USA* 1980;77:2936–40.
- [31] Fleck RA, Athwal H, Bygraves JA, Hockley DJ, Feaver IM, Stacey GN. Optimization of NB-4 and HL-60 differentiation for use in opsonophagocytosis assays. *In Vitro Cell Dev Biol Anim* 2003;39:235–42.
- [32] Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whittin JC, et al. Standardization of an opsonophagocytic assay for measurement of functional antibody activity against *Streptococcus pneumoniae* using differentiated HL-60 cells. *Clin Diagn Lab Immunol* 1997;4:415–22.
- [33] Neuhauser M, Bretz F. Nonparametric all-pairs multiple comparisons. *Biomet J* 2001;5:571–80.
- [34] Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines WHO Technical Report Series No. 927, Annex 2. World Health Organization; 2005. <http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.html>.
- [35] Musher DM, Groover JR, Reichner MR, Riedo FX, Schwartz B, Watson DA, et al. Emergence of antibody to capsular polysaccharide of *Streptococcus pneumoniae* during the outbreaks of pneumonia: association with nasopharyngeal colonization. *Clin Infect Dis* 1997;24:441–6.
- [36] Brandao AP, de Oliveira TC, de Cunto Brandileone MC, Goncalves JE, Yara TI, Simonsen V. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. *Vaccine* 2004;23:762–8.
- [37] Glodblat D, Hussain M, Andrew N, Ashton L, Vitta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of *Streptococcus pneumoniae* in adults: a longitudinal household study. *J Infect Dis* 2005;191:387–93.
- [38] Fleck RA, Romero-Steiner S, Nham MN. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. *Clin Diagn Lab Immunol* 2005;12:19–27.

- [39] Vidarsson G, Sigurdardottir ST, Gudnason T, Kjartansson S, Kristinsson KG, Ingolfsdottir G, et al. Isotype and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. *Infect Immun* 1998;66:2866–70.
- [40] Lortan LE, Kaniuk AS, Monteil MA. Relationship of in vitro phagocytosis of serotype 14 *Streptococcus pneumoniae* to specific class and IgG subclass antibody in healthy adults. *Clin Exp Immunol* 1993;91:54–7.
- [41] Puumalainen T, Ekstrom N, Zeta-Capeding R, Ollgren J, Jousimies K, Lucero M, et al. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. *J Infect Dis* 2003;187:1704–8.
- [42] Wuorimaa TK, Dagan R, Bailleux F, Haikala R, Ekstrom N, Eskola J, et al. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent conjugated pneumococcal vaccine. *Vaccine* 2005;23:5328–32.
- [43] Ekstrom N, et al. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Vaccine Trial. *Infect Immun* 2007;75:1794–800.



医学と医療の最前線

肺炎球菌ワクチン—5年後の再接種の是非—

大石 和徳

日本内科学会雑誌 第97巻 第4号別刷

2008年4月10日

肺炎球菌ワクチン—5年後の再接種の是非—

大石 和徳

要 旨

肺炎球菌ワクチン接種の成人における市中肺炎の重症化阻止効果が明らかになり、本邦における高齢者における接種率も徐々に増加してきている。肺炎球菌ワクチンの再接種を希望する患者が増加する状況下で、本邦ではその再接種が未だ禁忌となっている事が問題視されている。現在までに、国内関連4学会から厚生労働省に対して再接種の要望書が提出されている。高齢者や慢性呼吸器疾患においては、肺炎球菌ワクチンの初回接種後の血清中特異IgG濃度は免疫原性の低い血清型によっては5年以内に接種前値以下に低下することから、再接種の承認が必要である。再接種による血清中特異IgG抗体応答は初回時のそれより低下するものの、副反応も重篤なものは無く安全である。本邦では通常65歳以上の高齢者に初回接種されることから、当面は初回接種の5年後の再接種の承認に向けて国民の意識を高めていく必要がある。

(日内会誌 97: 836-841, 2008)

**Key words:** 肺炎球菌ワクチン, 再接種, 特異IgG抗体, 副反応

はじめに

肺炎球菌は最も重要な呼吸器病原性菌である。本菌はグラム陽性双球菌で多糖体(ポリサッカライド)からなる莢膜に覆われており、この莢膜ポリサッカライド(CPS)には少なくとも90の莢膜血清型が存在する。このCPS特異的IgGによる補体依存性オプソニン活性は肺炎球菌感染症に対する宿主感染防御の中心的役割を果たすとされている。

米国で肺炎球菌ポリサッカライドワクチンが承認されて以来、これまでに多くの肺炎球菌ワクチンによる免疫能正常者における菌血症を伴う肺炎、髄膜炎などの侵襲性肺炎球菌性感染症に対する予防効果に関する報告がある。これら

の研究から、米国Advisory Committee on Immunization Practice (ACIP)は肺炎球菌ワクチン接種を表1に示す対象者に推奨している<sup>1)</sup>。本邦では肺炎球菌ワクチンは1988年に承認され、最近になって公費負担を行う地方自治体も64カ所の市区町村と増加し、65歳以上の高齢者における接種率は現在3.9%に達している。このような情勢から、肺炎球菌ワクチンの再接種を患者が要望するケースが増加している。しかしながら、我が国においては肺炎球菌ワクチンの再接種は禁忌となっている。日本呼吸器学会、日本感染症学会、日本化学療法学会、日本臨床微生物学会から、厚生労働省に対して再接種の承認要望書が提出されている。本稿では肺炎球菌ワクチンの今日の位置付けに加え、再接種の是非と今後の問題解決策について記述する。

おおいし かずのり：大阪大学微生物病研究所、感染症国際研究センター

表 1. 肺炎球菌ワクチンの適応および勧告

接種推奨の対象	期待される有効性	再接種
65 歳以上	A	接種後 5 年以上経過しており、かつ前回接種が 65 歳未満であった場合
2 ~ 64 歳で 慢性心疾患、慢性肺疾患、糖尿病	A	必要なし
2 ~ 64 歳で 慢性肺疾患、髄液漏、 アルコール依存症	B	必要なし
2 ~ 64 歳で 機能的または解剖的無脾症	A	・ 10 歳以上：前回接種後 5 年以上経過 ・ 10 歳あるいは未満：前回接種後 3 年
2 ~ 64 歳で 肺炎球菌全身性感染のリスクの高い 人種・民族	C	必要なし
2 歳以上の免疫不全状態 ① HIV 感染、②悪性腫瘍、 ③ネフローゼ症候群、慢性腎不全、 ④免疫抑制状態（臓器移植、長期にわたるステロイド療法など）	C	・ 初回接種後 5 年以上経過 ・ 10 歳以上で前回接種後 3 年

期待される有効性

A：疫学的、臨床的に高い有効性あり

B：疫学的、臨床的に満足できる有効性あり

C：有効性は必ずしも証明されていないが、ハイリスクであり個々における有効性を期待

免疫能正常者では 65 歳以上の高齢者、2 ~ 64 歳で慢性心疾患、慢性肺疾患、糖尿病の患者、無脾状態の患者に対して明らかな証拠に基づく A ランクの推奨をしている。免疫正常者でも 2 ~ 64 歳で慢性肝疾患、アルコール中毒、脳脊髄液漏の患者には B ランク（中等度の証拠）、HIV 感染者を含む免疫不全患者には C ランク（明かな有効性の証明が無い）の推奨をしている。

症化阻止効果が示唆される。

## 1. 肺炎球菌ワクチンの肺炎に対する効果

肺炎球菌感染症の大半は菌血症を伴わない（非侵襲性）肺炎である。今日まで、肺炎球菌ワクチンの成人における肺炎の予防効果は明らかになっていないが、Fismanらは彼らの実施した 62,918 例の市中肺炎で入院した成人の成績から、先行する肺炎球菌ワクチン接種が市中肺炎患者の入院中の死亡を 50% 減少させ、呼吸不全を 33% 減少させると報告している<sup>3)</sup>。同様に、Jhonstoneらも 3,415 例の市中肺炎患者の前向き研究から、肺炎球菌ワクチン接種により市中肺炎患者の死亡もしくは集中治療室入室の頻度を 40% 減少できるとしている<sup>4)</sup>。このような最近の報告から、肺炎球菌ワクチンの成人の市中肺炎に対する重

## 2. 肺炎球菌ワクチンの慢性閉塞性肺疾患（COPD）における効果

本邦における COPD 患者数は 500 万人以上に及ぶとされている。COPD は市中肺炎のリスクグループであり、またしばしば急性増悪を惹起する。肺炎球菌はこれらの病態でも主要な原因菌である。最近、Alfagemeらは COPD 患者を対象とした前向き無差別比較試験の結果を報告している。彼らは、肺炎球菌ワクチン接種により 65 歳以下の COPD 患者では 76% の肺炎予防効果を認め、また %1 秒量が 40% 未満の COPD 患者においては 48% の予防効果を認めたとしている<sup>5)</sup>。Global Initiative for Chronic Obstructive Lung

表2. 応答者と低応答者間のワクチン接種前, 1ヵ月後の血清中特異IgG濃度

血清型	時期	IgG 相乗平均 ( $\mu\text{g}/\text{ml}$ ) (95% CI)		
		全体 (n = 84)	応答者 (n = 58)	低応答者 (n = 26)
6B	前	4.33(3.51~5.36)	3.9 (3.01~5.04)	5.48(3.80~7.89)
	1ヵ月後	6.44(5.11~8.11)**	6.81(5.04~9.21)**	5.68(4.02~8.03)
14	前	6.35(5.25~7.68)	5.82(4.71~7.17)	7.73(5.14~11.63)
	1ヵ月後	14.84(11.51~19.14)**	18.42(13.45~25.22)**	9.16(6.17~13.60)*#
19F	前	5.25(4.29~6.43)	4.74(3.70~6.07)	6.62(4.62~9.48)
	1ヵ月後	7.27(6.04~8.75)**	7.63(6.09~9.55)**	6.53(4.63~9.21)
23F	前	3.05(2.53~3.67)	2.91(2.37~3.57)	3.37(2.24~5.07)
	1ヵ月後	6.51(5.01~8.46)**	8.39(6.10~11.52)**	3.7 (2.45~5.58)#

\*\* $P < 0.01$ , \* $P < 0.05$  (前値に対し); # $P < 0.05$  (応答者の接種1ヵ月後に対し)

Diseases (GOLD) のガイドライン 2006 年は, この肺炎球菌ワクチンのCOPDに対する効果をエビデンスBとして記載している。

一方, スエーデンにおいてインフルエンザワクチンと肺炎球菌ワクチンによる高齢者を対象とした大規模な前向き研究が実施され<sup>9)</sup>, 両ワクチン接種群では, 非接種群に対して, 肺炎球菌性肺炎の発症率, および死亡率の有意な減少が認められている。本邦では 65 歳以上の高齢者に対してインフルエンザワクチンが定期接種化されていることから, 今後は肺炎球菌ワクチン単独の効果よりも肺炎球菌ワクチンとインフルエンザワクチンの併用接種の効果を評価するのが現実的と考えられる。最近, 我々は慢性肺疾患患者におけるインフルエンザワクチンと肺炎球菌ワクチンの併用接種の肺炎および急性増悪に対する効果を評価する目的で, 前向き無作為比較研究を実施した。その結果, インフルエンザワクチンと肺炎球菌ワクチンとの併用接種が, インフルエンザワクチン単独接種に比較して, 慢性肺疾患, とりわけCOPD患者の急性増悪を有意に減少させることを明らかにしている。COPDの急性増悪にも高額な医療費がかかることから, 併用接種による費用対効果が期待できる。

### 3. 肺炎球菌ワクチン初回接種後の特異免疫応答とその維持

肺炎球菌ワクチン接種後に感染防御抗体として機能する血清型特異抗体は一般に 5 年間は維持されるとされている。しかしながら, 宿主側要因や血清型により肺炎球菌ワクチン接種後の特異抗体応答の程度や抗体濃度の維持期間は異なっている。また, 肺炎球菌ワクチンに対する低応答者が存在することも知られている。筆者らは 84 例の慢性肺疾患患者 (平均 68.1 歳) に肺炎球菌ワクチンを接種し, 接種後 2 年間の主要 4 血清型に対する血清中特異IgG濃度を第三世代 EIA法で測定した<sup>6)</sup>。4 血清型のすべてにおいて接種 1ヵ月後の特異IgG濃度が接種前値の 2 倍以下であった症例を低応答者と定義したところ, 84 例中 26 例 (31%) が低応答者であった。84 例中の応答者と低応答者の接種前後の特異IgG濃度を表 2 に示した。近年の肺炎球菌コンジュゲートワクチンの研究から, 侵襲性肺炎球菌感染症を予防できる特異IgG閾値濃度は  $0.35\mu\text{g}/\text{ml}$  とされているが, 慢性肺疾患患者の血清中特異IgG濃度はどの血清型においてもワクチン接種前からこの閾値より高値であることが注目される。この高い血清中特異IgG抗体濃度が慢性肺疾患患者において肺炎球菌ワクチンの低応答者が多かつ